|   News

Cambridge biotech startup grabs $65M to tackle liver disease

A newly launched biotech company has secured $65 million in financing as it seeks to develop the first-ever treatment for a disorder that its co-founder described as “the life being squeezed out of the liver.” Cambridge-based Akero Therapeutics is focused on non-alcoholic steatohepatitis, or NASH, a disease in which liver fat accumulates in the body, sometimes leading to liver failure. NASH affects an estimated 16 million Americans, but there are currently no approved drugs targeting the disorder. Nationwide, only a handful of treatments are in late-stage clinical trials.

Read more.